San Antonio Breast Cancer Symposium (SABCS)

Since 1977, the Symposium’s mission has been to provide state-of-the-art information on breast cancer research. From a 1-day regional conference, the Symposium has grown to a 5-day program attended by a broad international audience of academic and private researchers and physicians from over 90 countries.

The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a broad spectrum of researchers, health professionals, and those with a special interest in breast cancer.

The ongoing BRIDGET (NCT05323955) trial is a single-arm, phase 2, multicenter study that is evaluating the addition of tucatinib to trastuzumab/pertuzumab or trastuzumab emtansine after local therapy in patients with HER2+ metastatic breast cancer (MBC) with isolated brain relapse or progression. Read More ›

Findings of a small multi-institution retrospective study do not indicate a clear increased risk for interstitial lung disease with sequential treatment of antibody–drug conjugates in patients with metastatic breast cancer (MBC). Read More ›

Findings of a retrospective single-institution study indicates that higher body mass index (BMI) was associated with better survival outcomes compared with lower BMI in patients with metastatic/recurrent breast cancer. Read More ›

The DESTINY-Breast-RESPOND trial is a multicenter, prospective, observational study of trastuzumab deruxtecan that is evaluating the effectiveness and tolerability of trastuzumab deruxtecan in patients with HER2+ or HER2-low unresectable and/or metastatic breast cancer (MBC) in a real-world setting. Read More ›

Real-world evidence from a single-center experience showed that pertuzumab was well tolerated in older patients with HER2+ breast cancer in the real-world setting; however, a quarter of patients discontinued treatment due to toxicities. Read More ›

HER2 gene amplification may have impact on CDK 4/6 inhibitor-therapy effectiveness in patients with metastatic breast cancer. Read More ›

Pooled analysis of the MONALEESA-2, -3, and -7 clinical trials finds elderly patients have survival benefits from treatment with ribociclib plus endocrine therapy. Read More ›

Focus group analysis of stakeholders in metastatic breast cancer treatment finds a need for accessible and patient-friendly terminology in metastatic breast cancer treatment-making discussions. Read More ›

The use of CDK4/6 inhibitors following radiotherapy demonstrated to be safe and effective in patients with HR+/HER2– advanced breast cancer who develop brain metastases. Read More ›

Recent retrospective study finds that receiving CDK4/6 inhibitor plus endocrine therapy improves progression-free survival in patients with HR+/HER2– metastatic breast cancer. Read More ›

Page 3 of 12

Conference Correspondent Coverage is Brought to You by the Publishers of:
CONQUER: the patient voice
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
The Oncology Nurse–APN/PA
The Oncology Pharmacist

Learn more about our family of publications.

View Our Publications